Prosiectau (125)

Vacation studentship  (27.06.2011  -  26.08.2011)

Vaccines manufacturing hub for LMIC Vax-Hub-Global  (01.09.2023  -  29.02.2028)

Validate ESMCP report  (03.07.2015  -  16.07.2015)

Validating and explaining the presenting skills assessment for medics  (01.07.2014  -  15.12.2018)

Validating exosomes as a novel therapeutic strategy using established models of Hepatocellular Carcinoma  (01.07.2018  -  15.04.2023)

Validating methylation sensing proteins as therapeutic targets  (01.07.2008  -  30.06.2013)

Validating prognostic biomarkers for colorectal cancer and determining their clinical utility  (01.11.2018  -  30.06.2025)

Validating the use of piezoelectric materials for novel application in bio-mechanical engineering  (01.04.2013  -  29.04.2014)

Validation and Development of Markers for Sheep Maternal Ability  (01.03.2023  -  31.05.2024)

Validation and examination of NGS Fragmentation reaction sizes using agilent tapestation  (01.03.2018  -  31.03.2019)

Validation and use of a model system to investigate topical treatment of vulval intraepithelial neoplasia  (01.01.2010  -  15.01.2013)

Validation in rodent models of a novel approach to treat mood disorders based on ERK signalling stimulation  (01.10.2016  -  30.09.2018)

Validation of a new AI solution to predict relapse at 5-10 years on histology slides in early breast cancer patients  (01.03.2024  -  28.02.2026)

Validation of an improved synthesis of 18F-Flumazenil  (01.08.2020  -  31.10.2021)

Validation of a novel adapted qSOFA score to predict death in Malawian children with suspected infection  (01.06.2020  -  31.07.2020)

Validation of a stem cell derived cartilage model for osteoarthritis research and drug screening  (21.12.2020  -  31.01.2022)

Validation of LIMK1 as a novel target in the treatment of breast cancer  (01.09.2021  -  28.02.2022)

Validation of nWASP (neural Wiskott-Aldrich Syndrome Protein) as a therapeutic target in chronic non-healing human wounds  (01.01.2014  -  31.12.2016)

Validation of nWASP (Neuronal Wiskott-Aldrich Syndrome Protein) as a therapeutic target in chronic and non-healing human wounds  (01.01.2014  -  30.06.2017)

Validation of pharmatracer for fdg production  (01.08.2013  -  31.07.2014)

Validation of Ras-ERK inhibitors to treat L-DOPA induce Dyskinesia  (01.01.2013  -  01.11.2014)

Validation of the findings that HPV methylation predicts response to treatment of VIN with imiquimod and cidofovir  (01.09.2019  -  31.12.2019)

Validation of the Mycoplasma IST3 performance  (04.02.2019  -  31.07.2019)

Validation of Tie2 as the first tumour vascular response biomarker for VEGF inhibitors: Optimising the design of a subsequent randomised discontinuation trial: VALTIVE1  (01.01.2020  -  30.09.2024)

Valleys learning portfolio  (01.01.2011  -  30.06.2011)